SCHEMBL756641

SCHEMBL756641

COc1ccc(Oc2ccc(C=O)c(F)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
CYP1A2 P05177 3/20 0.51
CYP2C19 P33261 2/20 0.51
LMNA P02545 1/20 0.51
CYP2C9 P11712 1/20 0.51
TRIM24 O15164 1/20 0.50
TYR P14679 1/20 0.50
TRIM33 Q9UPN9 1/20 0.50
CYP1A1 P04798 1/20 0.49
CYP1B1 Q16678 1/20 0.49
ERN1 O75460 4/20 0.46
CYP2A6 P11509 1/20 0.46
AMY1A P0DUB6 1/20 0.43
LTA4H P09960 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
NFE2L2 Q16236 1/20 0.41
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL245504 0.89 ALDH1A1 (0.63) ALDH1A1CYP1A2CYP2C19LMNACYP2C9
Hydrochloric Acid SCHEMBL28823895 0.87 ALDH1A1 (0.61) ALDH1A1CYP1A2CYP2C19LMNACYP2C9
SCHEMBL24181300 0.86 TEAD4 (0.41) ALDH1A1CYP1A2CYP2C19LMNACYP2C9
SCHEMBL6142714 0.86 ALDH1A1 (0.42) ALDH1A1CYP1A2CYP2C19LMNACYP2C9
SCHEMBL23709919 0.84 LMNA (0.50) ALDH1A1CYP1A2CYP2C19LMNACYP2C9
SCHEMBL1125382 0.83 ERN1 (0.53) ALDH1A1CYP1A2CYP2C19LMNACYP2C9
SCHEMBL24313432 0.83 PRKDC (0.41) ALDH1A1CYP1A2CYP2C19LMNACYP2C9
SCHEMBL24512757 0.83 TDP1 (0.44) ALDH1A1ERN1
SCHEMBL26980167 0.81 SOS1 (0.38) ALDH1A1CYP1A2LMNATRIM24TYR
SCHEMBL16507404 0.81 ALDH1A1 (0.54) ALDH1A1CYP1A2CYP2C19LMNACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916589-B2 Bradykinin B1-antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-12-23 US disclosed
EP-2188254-B1 NOVEL BRADYKININ B1-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2012-03-21 EP disclosed
US-20110263626-A1 NOVEL BRADYKININ B1-ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 US disclosed
EP-2188254-A1 NOVEL BRADYKININ B1-ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2010-05-26 EP disclosed
WO-2009027450-A1 NOVEL BRADYKININ B1-ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263626-A1 NOVEL BRADYKININ B1-ANTAGONISTS BDKRB1, BDKRB2, EDNRB ALDH1A1 2920/4885CYP1A2 1724/4885CYP2C19 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.